Intellia Therapeutics, Inc.
Company Stats
- Market Cap
- $1.7B
- as of Sep 30, 2026
- Shares Outstanding
- 140.1M
- Free Float
- 93.9%
Income Statement
- Revenue
- $67.7M
- Operating Income
- -$441.0M
- Net Income
- -$412.7M
- EBITDA
- -$431.2M
- Revenue Growth, 3Y
- 9.1%
- FCF Margin, 3Y Avg
- -774.2%
- FCF Margin, Worst Year
- -1124.9%
Cash Flow
- Free Cash Flow
- -$395.9M
- FCF Yield
- -23.4%
- Owner FCF Yield
- -28.2%
Balance Sheet
- Cash & Equivalents
- $155.5M
Returns & Capital
- SBC, 3Y Avg
- $122.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $67.7M | -$395.9M | -585.0% |
| FY2024 | $57.9M | -$354.7M | -612.8% |
| FY2023 | $36.3M | -$408.1M | -1124.9% |
| FY2022 | $52.1M | -$346.8M | -665.5% |
| FY2021 | $33.1M | -$237.8M | -719.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Utilities Lead Quarterly Dilution as Materials Buybacks Gain